Xiaoling Xiong
Medical Practice in Flushing, NY
License number
New Jersey 25MA09918400
Issued Date
May 7, 2016
Expiration Date
Jun 30, 2017
Category
Medical Examiners
Type
Medical Doctor
Address
Address
Flushing, NY
Professional information
See more information about Xiaoling Xiong at trustoria.com
Peptide Inhibitors Of Abl Kinases
Peptide Inhibitors Of Abl Kinases
US Patent:
2010018, Jul 22, 2010
Filed:
Nov 29, 2006
Appl. No.:
12/095728
Inventors:
Leszek Kotula - Marlboro NJ, US
Xiaoling Xiong - Fresh Meadows NY, US
Xiaoling Xiong - Fresh Meadows NY, US
International Classification:
A61K 38/16, C07K 7/08, C07K 14/00, C07K 17/00, A61K 38/10, A61P 35/00
US Classification:
514 12, 530327, 530324, 530350, 514 14
Abstract:
Provided are purified compounds comprising SEQ ID NO:1, where the tyrosine at residue (10) is phosphorylated. Also provided are purified compounds comprising SEQ ID NO:1, where the amino acid sequence of the compound is less than 400 amino acids. Additionally provided are methods of determining whether an agent is a candidate inhibitor of an Abl kinase. Further provided are methods of inhibiting an Abl kinase. Also provided are methods of treating a patient having a condition characterized by a mutant AbI kinase. Additionally provided are methods of treating a patient at risk for a condition characterized by a mutant AbI kinase. Methods of labeling an AbI kinase are also provided. Additionally, methods of isolating an Abl kinase from a tissue are provided.
Peptide Inhibitors Of Abl Kinases
Peptide Inhibitors Of Abl Kinases
US Patent:
2012019, Jul 26, 2012
Filed:
Mar 7, 2012
Appl. No.:
13/414422
Inventors:
Leszek Kotula - Marlboro NJ, US
Xiaoling Xiong - Fresh Meadows NY, US
Xiaoling Xiong - Fresh Meadows NY, US
Assignee:
NEW YORK BLOOD CENTER, INC. - New York NY
International Classification:
G01N 33/53
US Classification:
435 78
Abstract:
Provided are purified compounds comprising SEQ ID NO:1, where the tyrosine at residue () is phosphorylated. Also provided are purified compounds comprising SEQ ID NO:1, where the amino acid sequence of the compound is less than 400 amino acids. Additionally provided are methods of determining whether an agent is a candidate inhibitor of an Abl kinase. Further provided are methods of inhibiting an Abl kinase. Also provided are methods of treating a patient having a condition characterized by a mutant Abl kinase. Additionally provided are methods of treating a patient at risk for a condition characterized by a mutant Abl kinase. Methods of labeling an Abl kinase are also provided. Additionally, methods of isolating an Abl kinase from a tissue are provided.